1062 related articles for article (PubMed ID: 30292481)
21. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Niederman MS; Alder J; Bassetti M; Boateng F; Cao B; Corkery K; Dhand R; Kaye KS; Lawatscheck R; McLeroth P; Nicolau DP; Wang C; Wood GC; Wunderink RG; Chastre J
Lancet Infect Dis; 2020 Mar; 20(3):330-340. PubMed ID: 31866328
[TBL] [Abstract][Full Text] [Related]
22. Activity of Bacteriophages in Removing Biofilms of
Fong SA; Drilling A; Morales S; Cornet ME; Woodworth BA; Fokkens WJ; Psaltis AJ; Vreugde S; Wormald PJ
Front Cell Infect Microbiol; 2017; 7():418. PubMed ID: 29018773
[No Abstract] [Full Text] [Related]
23. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
[TBL] [Abstract][Full Text] [Related]
24. Isolation and Characterization of Three Pseudomonas aeruginosa Viruses with Therapeutic Potential.
Wang X; Tang J; Dang W; Xie Z; Zhang F; Hao X; Sun S; Liu X; Luo Y; Li M; Gu Y; Wang Y; Chen Q; Shen X; Xu L
Microbiol Spectr; 2023 Jun; 11(3):e0463622. PubMed ID: 37125933
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
26. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
28. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
30. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the effectiveness of silver-coated dressing, chlorhexidine acetate (0.5%), citric acid (3%), and silver sulfadiazine (1%) for topical antibacterial effects against the multi-drug resistant Pseudomonas aeruginosa infecting full-skin thickness burn wounds on rats.
Yabanoglu H; Basaran O; Aydogan C; Azap OK; Karakayali F; Moray G
Int Surg; 2013; 98(4):416-23. PubMed ID: 24229034
[TBL] [Abstract][Full Text] [Related]
32. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial.
Edmonds M; Lázaro-Martínez JL; Alfayate-García JM; Martini J; Petit JM; Rayman G; Lobmann R; Uccioli L; Sauvadet A; Bohbot S; Kerihuel JC; Piaggesi A
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):186-196. PubMed ID: 29275068
[TBL] [Abstract][Full Text] [Related]
33. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
[TBL] [Abstract][Full Text] [Related]
34. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of bactericidal effects of bacteriophage and gentamicin combination regimen against Staphylococcus aureus and Pseudomonas aeruginosa strains in a mice diabetic wound model.
Jokar J; Abdulabbas HT; Javanmardi K; Mobasher MA; Jafari S; Ghasemian A; Rahimian N; Zarenezhad A; ُSoltani Hekmat A
Virus Genes; 2024 Feb; 60(1):80-96. PubMed ID: 38079060
[TBL] [Abstract][Full Text] [Related]
36. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
37. Comparison of silver sulfadiazine and gentamicin for topical prophylaxis against burn wound sepsis.
Snelling CF; Ronald AR; Waters WR; Yaworski DS; Drulak K; Sunderland M
Can Med Assoc J; 1978 Sep; 119(5):466-70. PubMed ID: 99223
[TBL] [Abstract][Full Text] [Related]
38. Antibacterial Efficacy of a Chitosan-Based Hydrogel Modified With Epsilon-Poly-l-Lysine Against Pseudomonas aeruginosa in a Murine-Infected Burn Wound Model.
Moon AY; Bailey EJ; Polanco JA; Kurata WE; Pierce LM
Mil Med; 2023 Nov; 188(Suppl 6):52-60. PubMed ID: 37948238
[TBL] [Abstract][Full Text] [Related]
39. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice.
Chadha P; Katare OP; Chhibber S
Microb Pathog; 2016 Oct; 99():68-77. PubMed ID: 27498362
[TBL] [Abstract][Full Text] [Related]
40. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
